De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges
Cancers · 30.06.2025 · 17 (13) · 2200
DOI: 10.3390/cancers17132200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.06.2025. Verfasst von Jacob Schmidt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, …. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Kidney transplantation is associated with an increased risk of renal cell carcinoma (RCC). This study aimed to evaluate the outcomes of de novo RCC in kidney transplant recipients (KTRs).
Methods
We retrospectively identified 50 de novo RCC cases among 4012 KTRs transplanted from 2005 to 2024. Data on patient characteristics and outcomes were collected. Propensity score matching (PSM) compared 34 localized RCC cases in KTRs with 34 non-transplant RCC cases. The statistical analyses used Kaplan–Meier estimates, the log-rank test, and the Cox regression.
Results
The RCC incidence was 0.64 per 1000 person-years, with a standardized incidence ratio of 4.40 (95% CI: 3.33–5.80). In the KTR cohort, clear cell RCC was present in 42%, and papillary RCC was present in 42%. RCC developed predominantly in native kidneys (92%). UICC stage I was present in 74%. The treatment for the non-metastatic RCC was nephrectomy in the majority of cases (91%). For the metastatic RCC, 71% received a tyrosine kinase inhibitor (TKI). In the KTR cohort, the 3- and 5-year overall survival (OS) rates were 85% and 72%, respectively, with a median OS of 199 months; the synchronous metastasized (M1) patients had a median OS of 14 months. Rejection, age, advanced UICC stage, higher pT stage, clinical positive lymph nodes, M1, and higher grade were significantly associated with poor OS. The 5-year OS (96% vs. 84%, p = 0.72) and MFS (92% vs. 93%, p = 0.61) were comparable in the PSM cohort between the KTRs and the non-KTRs in the localized RCC.
Conclusions
KTRs have a higher risk of RCC and present at a localized stage with comparable OS rates to non-transplant RCC patients. Adverse tumor characteristics, including synchronous metastases, significantly affect the prognosis, highlighting the need for surveillance and individualized treatment, particularly for metastatic RCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany.
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Radiology, 10117 Berlin, Germany.
- Department of Urology, Evangelisches Krankenhaus Koenigin Elisabeth Herzberge, 10365 Berlin, Germany.
ORCID-Profile: Jacob Schmidt, Lukas Kurz, Bernhard Ralla, Markus H Lerchbaumer
Zitieren
APA
Schmidt, J., Lehnert, M., Lichy, I., Plage, H., Jeutner, J., Kurz, L., Ralla, B., Lerchbaumer, M. H., Schlomm, T., Friedersdorff, F., Maxeiner, A., & Peters, R. (2025). De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges. Cancers, 17(13), 2200. https://doi.org/10.3390/cancers17132200
Vancouver
Schmidt J, Lehnert M, Lichy I, Plage H, Jeutner J, Kurz L, et al. De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges. Cancers. 2025;17(13):2200. doi:10.3390/cancers17132200
BibTeX
@article{Schmidt2025,
author = {Schmidt, Jacob and Lehnert, Malte and Lichy, Isabel and Plage, Henning and Jeutner, Jonathan and Kurz, Lukas and Ralla, Bernhard and Lerchbaumer, Markus H and Schlomm, Thorsten and Friedersdorff, Frank and Maxeiner, Andreas and Peters, Robert},
title = {De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges},
journal = {Cancers},
year = {2025},
volume = {17},
number = {13},
pages = {2200},
doi = {10.3390/cancers17132200}
}
EUVIMED